We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+13.73%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$178M
AUM Growth
+$74.8M
Cap. Flow
+$62M
Cap. Flow %
34.75%
Top 10 Hldgs %
63.3%
Holding
53
New
10
Increased
20
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.4M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.04M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2.09M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.96M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$936K

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$24.3M
2
MDVN
MEDIVATION, INC.
MDVN
+$3.11M
3
IQV icon
IQVIA
IQV
+$1.42M
4
HOLX
Hologic
HOLX
+$571K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$291K

Sector Composition

Rank Sector Weight
1 Healthcare 42.47%
2 Real Estate 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$8.93B
$2.8M 1.57%
76,439
+5,571
+8% +$174K
GSK icon
27
GSK
GSK
$107B
$2.59M 1.45%
48,000
+8,000
+20% +$439K
BMY icon
28
CALL
Bristol-Myers Squibb
BMY
$129B
$2.43M 1.36%
+45,000
New +$2.89M
PCRX icon
29
Pacira BioSciences
PCRX
$1.04B
$1.71M 0.96%
+50,000
New +$1.96M
MDCO
30
DELISTED
Medicines Co
MDCO
$1.06M 0.59%
28,000
+14,115
+102% +$532K
PRTK
31
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.04M 0.58%
80,000
+42,335
+112% +$561K
ADMS
32
DELISTED
Adamas Pharmaceuticals
ADMS
$985K 0.55%
60,000
+14,802
+33% +$225K
SNR
33
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$966K 0.54%
83,700
– –
CFRX
34
DELISTED
ContraFect Corporation
CFRX
$744K 0.42%
+375
New +$736K
LABU icon
35
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$517M
$714K 0.4%
732
– –
SDS icon
36
ProShares UltraShort S&P500
SDS
$435M
$656K 0.37%
400
– –
PTLA
37
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$568K 0.32%
+25,000
New +$587K
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.46B
$502K 0.28%
7,074
– –
CPHD
39
DELISTED
Cepheid Inc
CPHD
$315K 0.18%
5,985
-797
-12% -$31.7K
ISEE
40
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$311K 0.17%
6,746
– –
IQV icon
41
IQVIA
IQV
$40.7B
$221K 0.12%
2,730
-18,790
-87% -$1.42M
ICPT
42
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$215K 0.12%
+1,306
New +$206K
UTHR icon
43
United Therapeutics
UTHR
$26.1B
$209K 0.12%
1,768
-296
-14% -$35.6K
SIOX
44
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$208K 0.12%
1,856
+182
+11% +$21.8K
JUNO
45
DELISTED
Juno Therapeutics, Inc.
JUNO
$208K 0.12%
+6,918
New +$215K
NBIX icon
46
Neurocrine Biosciences
NBIX
$18.2B
$206K 0.12%
+4,068
New +$203K
IOVA icon
47
Iovance Biotherapeutics
IOVA
$2.04B
$194K 0.11%
23,594
-632
-3% -$5.35K
GRFS
48
Grifois
GRFS
$5.55B
$189K 0.11%
11,849
+661
+6% +$10.9K
MCRB icon
49
Seres Therapeutics
MCRB
$45M
$172K 0.1%
700
-317
-31% -$111K
NVAX icon
50
Novavax
NVAX
$1.21B
$54K 0.03%
1,289
-166
-11% -$21.4K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q3 2016 Portfolio in Review

As of Q3 2016, Opus Point Partners Management held 53 positions worth $178M, up 72% from $104M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management deployed $62M of net new capital in Q3 2016, opening 10 new positions and adding to 20 existing holdings. Its largest new stake was ProShares Ultra NASDAQ Biotechnology: 85,000 shares worth $4.12M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 62% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was IQVIA, an estimated $1.42M trimmed.

  • Opus Point Partners Management's largest Q3 2016 buy was ProShares Ultra NASDAQ Biotechnology: 85,000 shares worth $4.12M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q3 2016, an estimated $4.4M increase.
  • Opus Point Partners Management's biggest Q3 2016 reduction was IQVIA, cutting an estimated $1.42M.
  • Opus Point Partners Management fully exited iShares Russell 2000 ETF in Q3 2016, selling an estimated $24.3M.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $178M portfolio in Q3 2016.
  • Opus Point Partners Management opened 10 new positions and closed 3 in Q3 2016.
  • Opus Point Partners Management's portfolio value rose 72% quarter-over-quarter to $178M.

Based on Opus Point Partners Management's 13F filing for Q3 2016, filed 14 Nov 2016.